Teaching and External Activities

Amplitude-case

…Since 2000

  • 2000-01
    • Ph.D. course in corporate finance (Finance 7808): 1 section, rating of 4.7
    • MBA financial decision-making (Finance 6429): 2 sections, ratings of 4.5 and 4.5
  • 2001-02
    • MBA financial decision-making (Finance 6429): 2 sections, ratings of 4.5 and 4.8
  • 2002-03
    • Ph.D. course in corporate finance (Finance 7808): 1 section, rating of 5.0
  • 2003-04
    • Ph.D. course in corporate finance (Finance 7446): 1 section, rating of 5.0
    • Ph.D. course in corporate finance (Finance 7808): 1 section, rating of 5.0
  • 2004-05
    • Ph.D. course in corporate finance (Finance 7446): 1 section, rating of 4.8
    • Ph.D. course in corporate finance (Finance 7808): 1 section, rating of 5.0
  • 2005-06
    • Undergrad financial management (Finance 4414): 3 sections, ratings of 4.2, 4.4, and 4.7
  • 2006-07
    • Ph.D. course in corporate finance (Finance 7446): 1 section, rating of 5.0
  • 2007-08
    • Ph.D. course in corporate finance (Finance 7446): 1 section, rating of 5.0
    • Ph.D. course in corporate finance (Finance 7808): 1 section, rating of 5.0
  • 2008-09
    • MBA financial decision-making (Finance 6429): 2 sections, ratings of 3.3 and 4.2
    • MBA private equity (Finance 6434): 1 section, rating of 4.6
  • 2009-10
    • Ph.D. course in corporate finance (Finance 7447): 1 section, rating of 4.9
  • 2010-11
    • Ph.D. advanced corporate finance (Finance 7808): 1 section, autumn 4.8
    • Undergrad financial management (Finance 4414): 2 sections, ratings of 4.5 and 4.6
  • 2011-12
    • Ph.D. corporate finance (Finance 7447): 1 section, rating of 5.0
  • 2012-13
    • Ph.D. corporate finance (Finance 7447): 1 section, rating of 5.0
    • Undergrad financial management (Finance 4414): 2 sections, ratings of 4.6 and 4.9
    • (note: response rates of only 8 out of 32 and 9 out of 33, typical of on-line evaluations)
  • 2013-14
    • Ph.D. advanced corporate finance (Finance 7808); 1 section, rating of 4.8
  • 2014-15
    • Ph.D. corporate finance (Finance 7447):  1 section rating of 5.0
    • Undergrad financial management (Finance 4414): 2 sections, ratings of 4.0 and 4.4
    • (note: response rates of below 25% in all 3 classes, typical of on-line evaluations)
  • 2015-16
    • Ph.D. advanced corporate finance (Finance 7808): 1 section, rating of 4.0
    • (note: responses from only 3 students)
  • 2016-17
    • Ph.D. corporate finance (Finance 7447): 1 section, rating of 5.0
    • (note: responses from 5 out of 8 students)
  • 2017-18
    • Ph.D. advanced corporate finance (Finance 7808): 1 section, rating of 5.0
    • (note: responses from 3 out of 6 registered students)
  • 2018-19 
    • Ph.D. corporate finance (Finance 7447):  1 section, rating of
    • (note: responses from x out of 9 registered students)
  • 2019-20
    • Ph.D. advanced corporate finance (Finance 7808): 1 section, rating of

Note: All teaching ratings are on a 1-5 basis, with 5 being the highest.


Selected External Activities (non-academic, compensated) Since 1993

  • Law firm of Petersen and Houpt, 1994
  • Roslyn Savings Bank IPO, 1996
  • Harris and Harris Corp., 1997
  • Catalyst Institute, 1998
  • BMC Software, 1999
  • U.S. Securities and Exchange Commission, 1999-2001
  • Law firm of Wolf Haldenstein Adler Freeman & Herz LLP, 2002-present
  • Office of the Attorney General of the State of NY, 2004-2006
  • Research Independence Council of the Independent Research Network, 2006-2007
  • U.S. Chamber of Commerce, 2006-2007
  • Vericimetry U.S. Small Cap Value Fund, Board of Trustees, 2011-2013
    • Chairman, Nominating Committee and Member, Audit Committee, 2011-2013
  • Law firm of Joel M. Weissman, P.A., 2011
  • Kauffman Foundation, 2011-2012
  • Delaware Investments: 2013
  • Forbes.com columnist, 2014-2016
  • Merrill Lynch (with Cornerstone), 2015
  • IOSCO training program, 2018, 2019
  • Ned Davis Research, 2020
  • Bank of America, 2021
  • Matterport (with Cornerstone), 2021
  • Program on International Financial Systems, 2021, 2022
  • Resera Capital, 2023-present
  • Evanoa Bioscience, 2023-present
  • Analysis Group, 2023-present